［1］ BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[2] SIMMS KT,STEINBERG J,CARUANA M,et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries,2020-99:A modelling study［J］.Lancet Oncol,2019,20(3):394-407.
[3] LIANG H,GRIFFITH CC,MA L,et al.The sensitivity of Pap cytology and HPV testing to detect incident cervical cancer:Prior testing results in 178 patients with invasive cervical cancer at a large general hospital in China［J］.J Am Soc Cytopathol,2016,5(2):64-70.
[4] ZHAO C,LI Z,NAYAR R,et al.Prior high-risk human papillomavirus testing and Papanicolaou test results of 70 invasive cervical carcinomas diagnosed in 2012:Results of a retrospective multicenter study［J］.Arch Pathol Lab Med,2015,139(2):184-188.
[5] BLATT AJ,KENNEDY R,LUFF RD,et al.Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices［J］.Cancer Cytopathol,2015,123(5):282-288.
[6] ZHENG B,LI Z,GRIFFITH CC,et al.Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China' s largest CAP-certified laboratory［J］.Cancer Cytopathol,2015,123(7):428-434.
[7] TAO X,ZHENG B,YIN F,et al.Polymerase chain reaction human papillomavirus (HPV) detection and HPV genotyping in invasive cervical cancers with prior negative HC2 test results［J］.Am J Clin Pathol,2017,147(5):477-483.
[8] PETRY KU,LIEBRICH C,LUYTEN A,et al.Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers［J］.Papillomavirus Res,2017,4(3):85-89.
[9] GE Y,MODY RR,OLSEN RJ,et al.HPV status in women with high-grade dysplasia on cervical biopsy and preceding negative HPV tests［J］.J Am Soc Cytopathol,2019,8(3):149-156.
[10] VAN ARSDALE A,PATTERSON NE,MAGGI EC,et al.Insertional oncogenesis by HPV70 revealed by multiple genomic analyses in a clinically HPV-negative cervical cancer［J］.Genes Chromosomes Cancer,2020,59(2):84-95.
[11] PIROG EC.Cervical adenocarcinoma:Diagnosis of human papillomavirus-positive and human papillomavirus-negative tumors［J］.Arch Pathol Lab Med,2017,141(12):1653-1667.
[12] PIROG EC,LLOVERAS B,MOLIJN A,et al.HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma,a worldwide analysis of 760 cases［J］.Mod Pathol,2014,27(12):1559-1567.
[13] HOLL K,NOWAKOWSKI AM,POWELL N,et al.Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias:Results from a European multinational epidemiological study［J］.Int J Cancer,2015,137(12):2858-2868.
[14] MOLIJN A,JENKINS D,CHEN W,et al.The complex relationship between human papillomavirus and cervical adenocarcinoma［J］.Int J Cancer,2016,138(2):409-416.
[15] RONCO G,DILLNER J,ELFSTRM KM,et al.Efficacy of HPV-based screening for prevention of invasive cervical cancer:Follow-up of four European randomised controlled trials［J］.Lancet,2014,383(9916):524-532.
[16] WRIGHT TC,STOLER MH,BEHRENS CM,et al.Primary cervical cancer screening with human papillomavirus:end of study results from the ATHENA study using HPV as the first-line screening test［J］.Gynecol Oncol,2015,136(2):189-197.
[17] ZHOU H,MODY RR,LUNA E,et al.Clinical performance of the Food and Drug Administration-approved high-risk HPV test for the detection of high-grade cervicovaginal lesions［J］.Cancer Cytopathol,2016,124(5):317-323.
[18] 陈静.宫颈癌筛查方法的现状与研究进展［J］.世界最新医学信息文摘,2019,19(1):46-47.
CHEN J.Current status and research progress of cervical cancer screening methods［J］.World Latest Medical Information Digest,2019,19(1):46-47.
[19] LEE JW,CHOI CH,CHOI JJ,et al.Altered microRNA expression in cervical carcinomas［J］.Clin Cancer Res,2008,14(9):2535-2542.
[20] GOCZE K,GOMBOS K,JUHASZ K,et al.Unique microRNA expression profiles in cervical cancer［J］.Anticancer Res,2013,33(6):2561-2567.
[21] PARK S,EOM K,KIM J,et al.MiR-9,miR-21,and miR-155 as potential biomarkers for HPV positive and negative cervical cancer［J］.BMC Cancer,2017,17(1):658.
[22] 伍恒英,彭苏珺,布俏雯,等.FAM19A4基因启动子甲基化在高危型HPV阴性宫颈癌诊断中的作用［J］.实用医学杂志,2019,35(5):683-687.
WU HY,PENG SJ,BU QW,et al.The role of FAM19A4 gene promoter methylation detection in the diagnosis of high-risk HPV-negative cervical cancer［J］.Journal of Practical Medicine,2019,35(5):683-687.
[23] LUTTMER R,DE STROOPER LM,DIJKSTRA MG,et al.FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women［J］.Br J Cancer,2016,115(5):579-587.
[24] DE STROOPER L,BERKHOF J,STEENBERGEN R,et al.Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test:A post hoc analysis in the POBASCAM trial with 14 year follow-up［J］.Int J Cancer,2018,143(6):1541-1548.
[25] 李智敏,曾俐琴,彭秀红,等.高危型HPV阴性子宫颈癌患者的临床病理特点［J］.中华妇产科杂志,2016,51(9):683-687.
LI ZM,ZENG LQ,PENG XH,et al.Analysis of clinical and pathological characteristics of high-risk HPV-negative carcinoma of the uterine cervix［J］.Chin J Obstet Gynecol,2016,51(9):683-687.
[26] 刘常燕,肖琳,王宇,等.高危型人乳头状瘤病毒阴性子宫颈癌患者的临床病理特征分析［J］.中国肿瘤临床与康复,2018,25(11):1329-1332.
LIU CY,XIAO L,WANG Y,et al.Clinicopathological features of high-risk types of HPV-negative cervical cancer［J］.Chinese Journal of Oncology and Rehabilitation,2018,25(11):1329-1332.
[27] 陈文增,陈亚侠.高危型人乳头瘤病毒阴性宫颈癌患者临床病理特征分析［J］.中国全科医学,2019,22(26):3179-3183.
CHEN WZ,CHEN YX.Clinical and pathological features of high-risk HPV-negative cervical cancer［J］.Chinese General Practice,2019,22(26):3179-3183.
[28] 黄山,杨英捷.HPV阴性宫颈癌的实验室验证及临床分析［J］.重庆医科大学学报,2019,44(12):1-6.
HUANG S,YANG YJ.Laboratory verification and clinical analysis of HPV-negative cervical cancer［J］.Journal of Chongqing Medical University,2019,44(12):1-6.
[29] RODRGUEZ-CARUNCHIO L,SOVERAL I,STEENBERGEN RD,et al.HPV-negative carcinoma of the uterine cervix:A distinct type of cervical cancer with poor prognosis［J］.BJOG,2015,122(1):119-127.
[30] NICOLS I,MARIMON L,BARNADAS E,et al.HPV-negative tumors of the uterine cervix［J］.Mod Pathol,2019,32(8):1189-1196.